Name: how bacteria outsmart antibiotics
Uploaded: 2026-03-12T13:35:59.000Z
Duration: 1 min 25 s
Channel: JoVE

Staphylococcus aureus se trouve couramment sur la peau humaine, mais c’est un agent pathogène opportuniste.Staphylococcus aureus résistant à la méthicilline, ou SARM (MRSA), est un type de S. aureus résistant à la méthicilline et à la plupart des autres antibiotiques β-lactamiques, comme la pénicilline.Les souches de MRSA modifient les protéines liant la pénicilline, ou PBP, ciblées par la plupart des β-lactames.Dans les souches de MRSA, cette résistance se développe en raison de la présence du gène mecA , qui code pour une protéine de liaison à la pénicilline modifiée appelée PBP2a.Ce PBP2a modifié présente une faible affinité de liaison pour les antibiotiques bêta-lactamiques, permettant au MRSA de synthétiser sa paroi cellulaire même en présence de ces médicaments.Dans de nombreuses souches de MRSA, les gènes régulateurs mecI et mecR1 contrôlant l’expression de mecA ne sont pas fonctionnels.Cela entraîne une expression continue de PBP2a et le développement d’une résistance stable.Le SARM peut présenter une résistance hétérogène, où seule une partie de la population bactérienne exprime une résistance, ou une résistance homogène, dans laquelle l’ensemble de la population est résistante.

mécanisme de la résistance aux antibiotiques dans le mrsa

Mechanism of Antibiotic Resistance in MRSA

La résistance aux antibiotiques chez les bactéries survient lorsque les micro-organismes développent la capacité de résister à des médicaments conçus pour les tuer ou inhiber leur croissance, rendant ainsi des traitements autrefois efficaces inutiles. Ce phénomène, provoqué par le changement génétique et la sélection sous exposition aux antibiotiques, représente une menace profonde pour la médecine moderne. Les mécanismes incluent des enzymes inactivantes de médicaments (par exemple, β-lactamases), des pompes d’efflux qui éjectent des antibiotiques, des mutations modifiant les cibles antibiotiques, une diminution de l’absorption des médicaments et l’acquisition de gènes de résistance par transfert horizontal de gènes. La résistance peut se développer de novo par mutation ou être rapidement disséminée par des éléments génétiques mobiles comme les plasmides et transposons. La pression de sélection due à un mauvais usage et à un usage excessif d’antibiotiques accélère l’émergence et la propagation de souches résistantes.Cliniquement, les infections résistantes aux antibiotiques sont plus difficiles à traiter, nécessitent souvent des médicaments plus toxiques ou coûteux, prolongent les séjours à l’hôpital, augmentent les coûts de santé et accélèrent la morbidité et la mortalité. Les estimations mondiales avertissent de millions de décès chaque année si les tendances de résistance se poursuivent.Staphylococcus aureus résistant à la méthicilline (MRSA) Le SARM est un paradigme de résistance aux antibiotiques. En acquérant le gène mecA via l’élément SCCmec, S. aureus produit la protéine de liaison à la pénicilline modifiée PBP2a, qui ne se lie pas aux médicaments β-lactamiques, conférant une large résistance aux pénicillines, céphalosporines et carbapénèmes. Le MRSA est apparu dans les hôpitaux (HA-MRSA) puis dans les communautés (CA-MRSA), stimulé à la fois par mutations et transfert horizontal de gènes. Cliniquement, le MRSA provoque de graves infections cutanées, des tissus mous, de la circulation sanguine et des pneumonies, souvent traitées par vancomycine, daptomycine ou linézolide, bien que ces alternatives présentent des limitations.Quelques autres exemples de résistance aux antibiotiques chez les bactéries :Entérocoques résistants à la vancomycine (ERV) et VRSA Les entérocoques résistants à la vancomycine sont apparus par l’acquisition d’opérons du gène van (par exemple, vanA). Ces gènes ont ensuite été transférés à S. aureus, ce qui a donné lieu à des souches rares mais dangereuses de S. aureus résistantes à la vancomycine (VRSA). Les infections à VRSA sont difficiles à traiter en raison du manque d’alternatives et constituent une grave préoccupation clinique malgré leur rareté.Streptococcus pneumoniae résistant aux médicaments (DRSP) S. pneumoniae a développé une résistance à la pénicilline par des mutations dans les protéines liant la pénicilline et aux macrolides via des gènes de méthyltransférase. Ces changements ont réduit l’efficacité thérapeutique pour la pneumonie, la méningite et l’otite moyenne, nécessitant des antibiotiques de niveau supérieur tels que les céphalosporines ou les fluoroquinolones, qui comportent leurs propres risques.En résumé, la résistance aux antibiotiques évolue par l’adaptation génétique et l’échange de gènes, avec un impact clinique significatif sur des agents pathogènes clés comme l’ARRM, le VRE/VRSA et le DRSP. Assurer une utilisation appropriée des antibiotiques, la surveillance des schémas de résistance, le contrôle des infections et le développement de nouveaux traitements restent essentiels pour atténuer cette crise sanitaire croissante.

Mécanisme de la résistance aux antibiotiques dans le MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, ...

https://cloudfront.jove.com/files/ftp_upload/40835/40835_article_thumb_40835.jpg

mechanism-of-antibiotic-resistance-in-mrsa

Education

Enseignement

JoVE Core

Microbiology

Microbiologie

Unit

Unité

Antimicrobial Agents

Agents antimicrobiens

KEY TERMS AND CONCEPTS

TERMES ET CONCEPTS CLÉS

how bacteria outsmart antibiotics

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working.

Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower drug uptake, or from new resistance genes gained through horizontal gene transfer, which is the movement of DNA between organisms.

Resistance may appear through new mutations or spread quickly through mobile genetic elements like plasmids and transposons. Misuse and overuse of antibiotics increase selection pressure, which helps resistant strains survive and spread. This makes antibiotic-resistant infections harder to treat and often forces doctors to use more toxic or more expensive drugs. These infections can also lead to longer hospital stays, higher healthcare costs, and more illness and death.

MRSA, short for methicillin-resistant Staphylococcus aureus, is a well-known example of this process. It acquired the mecA gene through the SCCmec element and makes an altered penicillin-binding protein called PBP2a. Because PBP2a does not bind beta-lactam drugs well, MRSA resists penicillins, cephalosporins, and carbapenems. MRSA first spread in hospitals as HA-MRSA and later in communities as CA-MRSA. It can cause skin, soft-tissue, bloodstream, and pneumonia infections, and it is often treated with vancomycin, daptomycin, or linezolid, although these options have limits.

Other resistant bacteria show the same problem in different forms. Vancomycin-resistant enterococci can gain van genes, such as vanA, and those genes can transfer to S. aureus to create rare but dangerous VRSA strains. Streptococcus pneumoniae can become resistant to penicillin through changes in penicillin-binding proteins and to macrolides through methyltransferase genes. These changes can make pneumonia, meningitis, and otitis media harder to treat and may require higher-tier antibiotics such as cephalosporins or fluoroquinolones.

Antibiotic resistance grows through genetic adaptation and gene exchange. Its impact reaches major pathogens such as MRSA, VRE, VRSA, and drug-resistant S. pneumoniae. Careful antibiotic use, resistance surveillance, infection control, and new treatments are important ways to slow this public health threat.

How Bacteria Outsmart Antibiotics

inhibitors of gram-positive cell wall synthesis

inhibitors-of-gram-positive-cell-wall-synthesis

How Antibiotics Block Bacterial Cell Walls

Bacterial cell walls are rigid structures built mainly from peptidoglycan. This mesh-like polymer gives bacteria strength and helps maintain cell shape. Because peptidoglycan synthesis is essential for growth, it is a major target for antibiotics. Beta-lactam antibiotics, such as penicillin, stop peptidoglycan synthesis in actively growing cells. They have a four-membered beta-lactam ring that mimics the D-alanyl-D-alanine dipeptide, which is the natural substrate for transpeptidase, also...

inhibitors of bacterial protein synthesis

inhibitors-of-bacterial-protein-synthesis

Aminoglycosides: How They Stop Bacteria

Aminoglycosides are bactericidal antibiotics that stop bacteria by targeting the ribosome and disrupting protein synthesis. They are highly potent drugs made of amino-modified sugars linked by glycosidic bonds to an aminocyclitol core, such as 2-deoxystreptamine or streptamine. Their strong positive charge helps them bind tightly to the negatively charged phosphate backbone of ribosomal RNA, especially the 16S rRNA of the 30S subunit in the bacterial 70S ribosome. These antibiotics act at the...

inhibitors of bacterial dna synthesis

Fluoroquinolone Antibiotics and Bacterial DNA

Fluoroquinolone antibiotics target bacterial DNA replication by blocking two key type II topoisomerases: DNA gyrase and topoisomerase IV. These enzymes help bacteria manage DNA supercoiling and separate chromosomes during replication. When they are disrupted, bacterial pathogens cannot copy DNA efficiently and infection can spread less effectively. Fluoroquinolones are synthetic versions of quinolones. They work by stabilizing the short-lived DNA-enzyme cleavage complex, which stops strand...

inhibitors of viral protein synthesis

Interferons Block Viral Replication

Interferons block viral replication by shutting down protein synthesis and activating the cell’s antiviral defenses. Viruses need the host cell’s translational machinery to make proteins, because they do not have the machinery to do this on their own. When a virus is detected, infected cells release interferons, which are cytokines, or signaling proteins, that warn nearby uninfected cells. Interferons bind to receptors on nearby cells and activate the JAK-STAT signaling pathway. This turns on...

inhibitors of virion release

Neuraminidase Inhibitors and Flu Spread

Influenza viruses spread when new virions leave an infected cell and reach nearby cells. Influenza A and B are negative-sense, single-stranded RNA viruses with segmented genomes. They depend on two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), to infect cells, make new viral particles, and release them. HA starts infection by binding to sialic acid on the surface of host epithelial cells. This binding helps the virus enter the cell by receptor-mediated endocytosis. After...

antiviral nucleoside inhibitors

How Antiviral Drugs Stop Viral Replication

Antiviral nucleoside inhibitors stop viruses by blocking DNA or RNA synthesis. These drugs are structural analogs, which means they look like natural nucleosides, the building blocks cells use to make genetic material. Because they resemble host nucleosides, they can interfere with viral polymerases and disrupt viral genome replication. Acyclovir is a guanosine analog with a three-carbon acyclic side chain. It mainly targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2...

antifungal agents

Amphotericin B and Fungal Membranes

Amphotericin B targets fungal cell membranes by binding to ergosterol, a sterol found mainly in fungal plasma membranes. Its amphipathic structure helps this selective binding. It has a hydrophobic polyene-lactone ring and a hydrophilic region with mycosamine and carboxylic acid groups. Weak binding to cholesterol can also affect human cells and helps explain the drug’s toxicity. One way amphotericin B kills fungi is through pore formation. In this model, amphotericin B-ergosterol complexes...

mechanism of antibiotic resistance in mrsa

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working. Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower...

anthelminthic agents

Helminth Drugs and How They Work

Helminth drugs work by attacking the weak points of parasitic worms. These anthelmintic medicines are different from drugs used against protozoa, because they are usually aimed at mature helminths rather than fast-dividing cells. They target the worm’s movement, glucose use, and microtubule structure to stop survival, reproduction, and location inside the host. Benzimidazoles are broad-spectrum anthelmintics that block tubulin polymerization, which means they interfere with microtubules, the...

clinical significance of antibiotic resistance

clinical-significance-of-antibiotic-resistance

MRSA: Host Adaptation and Transmission

MRSA, or methicillin-resistant Staphylococcus aureus, is a major public health threat. It resists beta-lactam antibiotics because it carries the mecA gene inside the staphylococcal cassette chromosome mec, or SCCmec. The mecA gene makes penicillin-binding protein 2a, which reduces how well methicillin and related beta-lactam drugs can bind. MRSA has spread into separate clonal lineages that affect both humans and animals. These lineages fit the One Health idea, which links human, animal, and...

inhibitors of virion maturation and assembly

inhibitors-of-virion-maturation-and-assembly

HIV Protease Inhibitors and Maturation

HIV protease inhibitors block a key step in virus maturation. In human immunodeficiency virus (HIV), infected cells make two long precursor proteins called polyproteins. These are Gag and Gag-Pol. Gag provides the virus structure. Gag-Pol carries important viral enzymes, including reverse transcriptase, integrase, and protease. After these polyproteins are made, they move to the host cell membrane. There, they help build an immature viral particle that buds from the cell surface. Budding...

antiprotozoal agents

Leishmaniasis and Trypanothione Reductase

Leishmaniasis is a parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. Treatment often relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. The way these drugs work has not been fully clear. One important target is trypanothione reductase, or TR, an enzyme that helps keep Leishmania in redox balance. TR is not found in mammalian hosts, so it is a...

key terms and concepts

Learn how bacteria become antibiotic resistant, from beta-lactamases and efflux pumps to MRSA, VRE, VRSA, and drug-resistant Streptococcus pneumoniae.

How Bacteria Outsmart Antibiotics | JoVE K12

JoVE Core Microbiology provides an engaging introduction to the microbial world and its influence on health, industry, and the environment. This comprehensive collection covers key concepts such as microbial structure, metabolism, genetics, and ecology. It introduces essential laboratory techniques and microscopy methods through visually engaging animations. Corresponding scientist-in-action videos bridge classroom concepts with real-world research and applications.

microbiology

How Bacteria Outsmart Antibiotics

Description

Transcript

Tags